Back to Search
Journal ArticleUnknown

Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis.

Author Affiliations
Massachusetts General Hospital, National Institute of Cardiovascular Diseases, Harvard University Press, Princeton University
Published InCirculation
Year1990
Citations77

Abstract

Recent experiments in vitro have shown that inhibition of human alpha 2-antiplasmin by a monoclonal antibody (MAb RWR) markedly enhances clot lysis by plasminogen activators. To extend these studies in vivo, we tested whether inhibition of clot or fibrin-bound alpha 2-antiplasmin by MAb RWR could enhance the lysis of a human clot by tissue-type plasminogen activator (t-PA) in a rabbit jugular vein thrombosis model. Compared with a saline placebo or a control antibody, MAb RWR significantly increased thrombolysis by endogenous plasminogen activator in rabbits to which no t-PA was administered (p less than 0.05). In rabbits that received t-PA, the combination of MAb RWR and t-PA caused significantly greater thrombolysis than equivalent doses of t-PA alone (p less than 0.05).…
View at Publisher

BORR does not host full-text PDFs. The button above takes you to the original publisher.